Acute electroretinographic changes during Sildenafil (Viagra) treatment for erectile dysfunction: Sildenafil-induced ERG changes

Documenta Ophthalmologica

Volumn 107, Issue 2, 2003, Pages 111-114

  Gabrieli, Corrado Balacco ^a   Regine, Federico ^a   Vingolo, Enzo M ^a   Rispoli, Edoardo ^a   Isidori, Aldo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

ERG; Naka Rushton; Sildenafil

Indexed keywords

SILDENAFIL;

ADULT; ARTICLE; B WAVE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; ELECTRORETINOGRAPHY; ERECTILE DYSFUNCTION; FUNCTIONAL ASSESSMENT; HUMAN; LIGHT EXPOSURE; LUMINANCE; MALE; PHOTOSENSITIVITY DISORDER; RETINA ROD; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STIMULUS RESPONSE; TREATMENT OUTCOME; VISUAL STIMULATION; VISUAL SYSTEM FUNCTION;

ELECTRORETINOGRAPHY; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RETINA; TIME FACTORS;

EID: 0345374614     PISSN: 00124486     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026271404384     Document Type: Article

References (7)

1. Fabbri A, Aversa A, Isidori A. Sildenafil and erectile dysfunction. J Endocrinol Invest 1999; 22: 486-92.
2. Center for Drug Evaluation and Research. A randomised, double-blind, placebo-controlled, crossover pilot study to investigate the effects of a single oral tablet dose of sildenafil (200mg) on visual function (electroretinogram, photostress, visual field and colour discrimination tests) in healthy male volunteers and patients with diabetic retinopathy: Study 148-232. In: Viagra (Sildenafil): Joint Clinical Review for NDA-20-895. Washington, DC: Center for Drug Evaluation and Research, Food and Drug Administration; 1998. Available at: http://www.fda.gov/cder/foi/nda/98/viagra/default.htm
3. Center for Drug Evaluation and Research. Phase I investigator-blind, placebo-controlled, evaluation of safety, toleration and pharmacokinetics of sildenafil following escalation single oral doses in healthy male volunteers: Study 140-004. In: Viagra (Sildenafil): Joint Clinical Review for NDA-20-895. Washington, DC: Center for Drug Evaluation and Research, Food and Drug Administration; 1998. Available at: http://www.fda.gov/cder/foi/nda/98/viagra/default.htm
4. Marmor MF, Kessler R Sildenafil (Viagra) and Ophthalmology. Surv Ophthalmol 1999; 44: 153 - 62.
5. Vobig AM, Klotz T, Staak M, Bartz-Schmidt KU, Engelmann U, Walter P. Retinal side effects of sildenafil Lancet 1999; 353: 375.
6. Marmor MF, Zrenner E, for the International Society for Clinical Electrophysiology of Vision. Standard for clinical electroretinography (1999 Update) this document was approved by the International Society for Clinical Electrophysiology of Vision in Eilat, Israel on April 15, Doc Ophthalmol (in press). Available at: http://www.iscev.org/aug/iscev/standards/erg1999.html
7. Behn D, Potter MJ. Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the γ-subunit of phosphodiesterase. Invest Ophthalmol Vis Sci 2001; 42: 523-527.